Breckenridge Launches Milnacipran HCl Tablets for Fibromyalgia Management

Breckenridge Launches Milnacipran HCl Tablets

Breckenridge Pharmaceutical, Inc., a prominent player in the U.S. generic medicine market and a subsidiary of Towa International, has announced the launch of Milnacipran HCl Tablets, a generic version of the branded medication Savella® (manufactured by AbbVie). This product, designed specifically for the management of fibromyalgia, reflects the company’s dedication to improving patient access to essential therapeutic options.

Importance of the Launch

Fibromyalgia, a chronic pain condition, can significantly impact the quality of life for those affected. Breckenridge’s introduction of Milnacipran HCl Tablets aims to provide a more affordable and accessible treatment alternative for patients struggling with this debilitating condition. The emphasis on affordability and quality aligns with Breckenridge's mission to enhance patient care through reliable medication access.

Product Details

Milnacipran HCl, a potent norepinephrine and serotonin reuptake inhibitor, specifically targets pain signals in the brain and is notable for its higher potency in blocking norepinephrine reuptake compared to serotonin. Unlike some alternatives, it does not have a direct effect on dopamine or other neurotransmitters. This unique mechanism of action can be particularly beneficial for fibromyalgia patients seeking relief from their symptoms.

The new tablets are available in various strengths: 12.5 mg, 25 mg, 50 mg, and 100 mg, and have been approved specifically for adult patients. It should be noted that Milnacipran HCl is not recommended for pediatric use, ensuring that the formulation is tailored for adult users who may require varying dosages based on their condition.

Commitment to Quality

Breckenridge’s partnership with Centaur Pharmaceuticals Pvt. Ltd. for the manufacturing of Milnacipran HCl Tablets underlines the company's commitment to maintaining high production standards. Centaur Pharmaceuticals is recognized for its extensive experience in pharmaceutical manufacturing and has established itself as a reliable provider, ensuring that the medications reach U.S. patients without compromising on quality.

Brian Guy, President and Chief Commercial Officer at Breckenridge, expressed that this launch marks a significant expansion of their product lineup and highlights their ongoing commitment to delivering high-quality generic drugs. He stated, "By prioritizing affordability and reliable access, Breckenridge supports patients in obtaining the medications they rely on every day."

Dr. Smita Phal, Executive Director of Centaur Pharmaceuticals, echoed this sentiment, emphasizing the valued partnership with Breckenridge in creating solutions that provide meaningful health benefits across patient populations. The collaboration not only enhances product availability but also strengthens the healthcare systems they support.

Conclusion

With the launch of Milnacipran HCl Tablets, Breckenridge Pharmaceuticals continues to pave the way in the realm of generic medicines, reinforcing their position as a staple in the pharmaceutical industry. As this product becomes available through retail and mail-order pharmacies, patients will have improved access to much-needed treatments, ultimately contributing to better management of fibromyalgia and enhancing overall patient outcomes.

For detailed prescribing information, including specific warnings and indications, please visit Breckenridge Pharmaceutical's official website.